The federal government’s rollout of medical cannabis rescheduling is accelerating, and the latest update from the Drug Enforcement Administration signals a major next step for licensed operators across the medical marijuana supply chain. After initially opening a registration portal only for dispensaries, the DEA has now confirmed that separate Schedule III registration forms for cultivators, manufacturers, testing laboratories, and distributors are expected to launch in the coming weeks.
This development follows the Trump administration’s April order to immediately reclassify state-regulated medical cannabis from Schedule I to Schedule III under the federal Controlled Substances Act. While the move stops short of full legalization, it creates a new pathway for state-licensed medical cannabis businesses to align with federal law, and potentially unlock significant tax and operational advantages.
DEA Registration Is Expanding Beyond Dispensaries
When the DEA first launched its registration process on April 29, only state-licensed medical dispensaries had access to a dedicated application portal. That created uncertainty for vertically integrated operators and other license holders such as growers, processors, and labs, many of whom were unsure whether they should use the standard DEA Form 225 or wait for additional guidance.
The agency has now clarified that both options are available. Businesses can continue submitting applications through the existing Form 225 using designated medical marijuana drug codes, but the DEA says new tailored forms are on the way for:
- Medical marijuana cultivators (bulk manufacturers)
- Manufacturers/processors
- Analytical laboratories
- Distributors
For businesses that already submitted an application using the standard form, the DEA says there is no need to reapply. Those applicants will be contacted directly to continue processing.
Why This Matters for Cannabis Businesses
The practical impact of Schedule III registration is significant. Most notably, federally compliant medical cannabis businesses may become eligible to deduct ordinary business expenses under federal tax law – something currently prohibited under Section 280E for Schedule I and II controlled substances.
For many operators, that could mean the difference between profitability and continued financial strain. The ability to write off payroll, rent, marketing, and operational expenses could reshape the economics of the medical cannabis sector almost overnight.
Additional potential benefits include:
- Improved access to traditional banking services
- Greater eligibility for mergers and acquisitions
- Possible interstate commerce opportunities in the future
- Easier access to institutional capital and exchange listings
- Potential export licensing as federal regulations evolve
For operators considering whether to apply, timing may matter. Businesses that register during the current 60-day expedited review window (ending June 26) may receive approval within six months and could gain a first-mover advantage as federal compliance frameworks take shape.
Application Risks and Legal Questions
Despite the opportunities, the registration process has raised concern among attorneys and operators alike.
The dispensary application asks whether anyone involved in ownership or operation has previously handled controlled substances without DEA authorization and whether the business handles recreational marijuana. For many currently licensed cannabis businesses, truthful answers to these questions may effectively amount to admitting participation in conduct that was federally illegal until the recent rescheduling order.
That creates a legal gray area. Providing false information on a federal application can carry serious penalties, but answering honestly may raise questions about past operations. Industry attorneys are closely watching how the DEA responds to this issue, particularly for businesses operating in states with both medical and adult-use programs.
The Congressional Research Service added to the discussion in a recent legal analysis, noting that all entities handling covered medical marijuana products – except end users – will likely need DEA registration to operate lawfully under the new federal framework.
A Complex New Federal Model
Another notable detail in the rescheduling rollout is the federal government’s unusual purchasing structure for cannabis production. To comply with international treaty obligations, the Justice Department says the federal government will technically purchase marijuana crops from registered producers and then sell them back to the same business (or an affiliated entity) at the same price plus an administrative fee.
This system is designed to satisfy treaty language requiring a government agency to act as the exclusive purchaser of cannabis production. It adds another layer of regulatory complexity that businesses will need to understand as federal oversight expands.
What Comes Next
While medical cannabis businesses can now begin entering a federally compliant system, adult-use operators remain in limbo. Recreational marijuana is still federally classified as Schedule I, and its future will be determined through an expedited administrative hearing process set to begin June 29.
That means many vertically integrated companies with both medical and adult-use operations may need to separate activities carefully to avoid jeopardizing their federal registrations.
The coming weeks are likely to be pivotal. As the DEA releases new application portals and more guidance emerges from the U.S. Department of the Treasury and Internal Revenue Service, cannabis businesses will need to make strategic decisions quickly.
The Bottom Line for Operators
Federal rescheduling is no longer theoretical, it is actively reshaping compliance requirements for state-licensed medical cannabis businesses. Operators who move early may gain substantial tax relief and strategic advantages, but the application process itself carries legal and operational risks that should not be overlooked.
For cannabis businesses, this is a moment to reassess licensing structures, tax strategies, entity separation, and long-term expansion plans. The regulatory environment is changing fast, and businesses that understand the federal implications now will be in a stronger position to capitalize on what comes next.
As federal cannabis regulations evolve, compliance and financial strategy are becoming more complex than ever. Canna Business Services helps cannabis operators navigate licensing, bookkeeping, tax planning, and operational compliance so your business stays prepared for every regulatory shift.
